Current clinical relevance of immunotherapy in metastatic renal cell cancer
Tóm tắt
Existing compilations of data recorded in clinical trials involving cytokines as single compounds and in combination with each other and with cellular immuno-effectors or chemotherapeutic agents are analyzed. Antitumor activity for interferon alpha (IFN-α) and for interleukin-2 (IL-2) could be established at 14.5% and 13.7%, respectively, when used in single-agent regimens with considerable toxicity for IL-2 at high, intravenous doses. When IL-2 is combined with cellular effectors, these side effects together with the problems associated with the complexity of culture techniques when adding LAK (lymphokine-activated killer) cells or CTILs (cytotoxic tumor-infiltrating lymphocytes) impact unfavorably on future clinical application, and this combination must be considered investigational. IFN-α or IL-2 coupled with a chemotherapeutic agent only exhibited a limited advantage over single cytokine administration. The most promising combination seems to be IFN-α combined with IL-2, giving improved prospects for nearly 30% of the patients with metastatic renal cell cancer (RCC), simultaneously allowing for significant reduction of toxicity and for an outpatient treatment. A precise assessment of the underlying immunologic mechanisms is needed, as are controlled prospective and randomized trials comparing the various cytokines with each other and with conventional approaches in single and combination regimens with the ultimate purpose of defining the role of biotherapy within a clinical strategy for metastatic RCC before it can be considered a standard treatment modality.
Tài liệu tham khảo
Abrams JS, Rayner AA, Wiernik PH, Parkinson R, Eisenberger M, Aronson FR, Gucalp R, Atkins MB, Hawkins MJ (1990) High-dose recombinant interleukin-2 alone: a regimen with limited activity in the treatment of advanced renal cell carcinoma. J Natl Cancer Inst 82:1202–1206
Aso Y, Tazaki H, Umeda T, Marumo K, and Interleukin-2 Research Group on Renal Cell Carcinoma (1989) Treatment of renal cell carcinoma with systemic administration of intermediate doses of recombinant human interleukin-2 alone. In: Murphy GP, Khoury S (eds) Therapeutic progress in urological cancers. Liss, New York, pp 681–688
Atkins MB, Sparano J, Fisher RI, Weiss GR, Margolin KA, Aronson FR, Sznol M, NCI Extramural IL-2 Working Group (ILWG) and New England Medical Center, Boston (1991) Randomized phase II trial of high dose IL-2 either alone or in combination with interferon alpha 2B (IFN) in advanced renal cell carcinoma (RCCA). Proc Annu Meet Soc Clin Oncol 10:166
Atzpodien J, Kirchner H (1990) Cancer, cytokines, and cytotoxic cells: interleukin-2 in the immunotherapy of human neoplasms. Klin Wochenschr 68:1–11
Atzpodien J, Körfer A, Franks CR, Poliwoda H, Kirchner H (1990) Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies. Lancet I:1509–1512
Atzpodien J, Körfer A, Evers P, Franks CR, Knüver-Hopf J, Lopez-Hänninen E, Fischer M, Mohr H, Dallmann I, Hadam M, Poliwoda H, Kirchner H (1990) Low-dose subcutaneous recombinant interleukin-2 in advanced human malignancy: a phase II outpatient study. Mol Biother 2:18–26
Bartsch HH, Adler M, Ringert RH, Boaziz C Symann M, Humblet Y, Bosly A, Franks CR, Palmer P, Evers MPJ, Israel L (1990) Sequential therapy of recombinant interferon-alpha (IFN-A) and recombinant interleukin 2 (IL-2) in patients with advanced renal cell cancer (RCC). Proc Annu Meet Am Soc Clin Oncol 9:143
Belldegrun A, Abi-Aad AS, DeKernion JB, Figlin RA (1991) Concomitant adminstration of recombinant human interleukin-2 (rIL-2) and Roferon-A in metastatic renal cell carcinoma (RCC): a UCLA phase II pilot study. J Urol 145:341A
Bergmann L, Weidmann E, Mitrou PS, Runne U, Keilholz U, Bartsch HH, Franks CR (1990) Interleukin-2 in combination with interferon-alpha in disseminated malignant melanoma and advanced renal cell carcinoma. A phase I/II study. Onkologie 13:137–140
Bukowski RM, Goodman P, Crawford ED, Sergi JS, Redman BG, Whitehead RP (1990) Phase II trial of high-dose intermittent interleukin-2 in metastatic renal cell carcinoma: a Southwest Oncology Group study. J Natl Cancer Inst 82:143–146
DeKernion JB, Berry D (1980) The diagnosis and treatment of renal cell carcinoma. Cancer 45 [Suppl. 7]: 1947–1956
Figlin R, Citron M, Whitehead R, DeKernion J, Desner M, Smith A, Jones G, Levitt D (1990) Low dose continuous infusion recombinant human interleukin-2 (rhIL-2) and Roferon-A: an active outpatient regimen for metastatic renal cell carcinoma (RCCa). Proc Am Soc Clin Oncol 9:142
Geertsen P, Herman G, Steven K, Zeuthen J, Hald t, Maase H vd (1990) A phase II trial of recombinant interleukin-2 by continuous infusion in advanced renal cell carcinoma. J Urol 143:319A
Horoszewicz JS, Murphy G (1989) An assessment of the current use of human interferon in therapy of urological cancers. J Urol 142:1173–1180
Itri LM, Sherman MI, Palleroni AV, Evans LM, Tran LL, Campion M, Chizzonite R (1989) Incidence and clinical significance of neutralizing antibodies in patients receiving recombinant interferon-α2a. J Interferon Res 9 [Suppl 1]:S9-S15
Kirchner H, Körfer A, Palmer PA, Evers P, De Riese W, Knüver-Hopf J, Hadam M, Goldman U, Franks CR, Poliwoda H, Atzpodien J (1990) Subcutaneous interleukin-2 and interferon-α2b in patients with metastatic renal cell cancer: the German outpatient experience. Mol Biother 2:145–154
Kirchner H, Körfer A, Evers P, Szamel MM, Knüver-Hopf J, Mohr H, Franks CR, Pohl U, Resch K, Hadam M, Poliwoda H, Atzpodien J (1991) The development of neutralizing antibodies in a patient receiving subcutaneous recombinant and natural interleukin-2. Cancer 67:1862–1864
Lindeman A, Höffken K, Schmidt RE, Diehl V, Kloke O, Gramm H, Hayungs J, Oster W, Böhm M, Kolitz JE, Franks CR, Herrmann F, Mertelsmann RH (1989) A phase-II study of low-dose cyclophosphamide and recombinant human interleukin-2 in metastatic renal cell carcinoma and malignant melanoma. Cancer Immunol Immunother 28:275–281
Lipton A, Harvey H, Hirsh M, Hopper K, Givant E, Levitt D, Zeffren J, Jones G (1990) Treatment of metastatic renal cell carcinoma with interleukin-2 and intramuscular interferon alpha-2a. J Cancer Res Clin Oncol 116 [Suppl II]: S923
Louie A (1991) American Cancer Society Meeting, Dallas, 6–8.2.1991
Marshall ME, Simpson W, Butler K, Fried A, Fer M (1989) Treatment of renal cell carcinoma with daily low-dose alpha-interferon. J Biol Response Mod 8:453–461
Mittelman A, Huberman M, Puccio C, Fallon B, Tessitore J, Savona S, Eyre R, Gafney E, Wick M, Skelos A, Arnold P, Ahmed T, Groopman J, Arlin Z, Zeffren J, Levitt D (1990) A phase I study of recombinant human interleukin-2 and alpha-interferon-2a in patients with renal cell cancer, colorectal cancer, and malignant melanoma. Cancer 66:664–669
Moore M, Christmas SE (1991) Cancer. In: Brostoff J, Scadding GK, Male D, Roitt IM (eds) Clinical immunology, Gower Medical, London New York Lippincott, Philadelphia, pp 20.1–20.16
Negrier S, Philip T, Stoter G, Fossa SD, Janssen S, Iacone A, Cleton FS, Eremin O, Israel L, Jasmin C, Rugarli C, Masse HVD, Thatcher N, Symann M, Bartsch HH, Bergmann L, Bijman JT, Palmer PA, Franks CR (1989) Interleukin-2 with or without LAK cells in metastatic renal cell carcinoma: a report of a European multicentre study. Eur J Cancer Clin Oncol 25 [Suppl 3]:S21-S28
Robertson CN, Linehan WM, Pass HI, Gomella LG, Haas GP, Bergman A, Merino M, Rosenberg SA (1990) Preparative cytoreductive surgery in patients with metastatic renal cell carcinoma treated with adoptive immunotherapy with interleukin-2 or interleukin-2 plus lymphokine activated killer cells. J Urol 144:614–618 (including editorial comments on pp 617–618
Rosenberg SA, Lotze MT, Muul LM, Leitman S, Chang AE, Ettinghausen SE, Matory YL, Skibber JM, Shiloni E, Vetto JT, Seipp CA, Simpson C, Reichert CM (1985) Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313:1485–1492
Rosenberg SA, Packard BS, Aebersold PM, Solomon D, Topalian SL, Toy ST, Simon P, Lotze MT, Yang JC, Seipp CA, Simpson C, Carter C, Bock S, Schwartzentruber D, Wei JP, White DE (1988) Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. N Engl J Med 319:1676–1680
Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT (1989) Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res 49:7086–7092
Stahel RA, Sculier JP, Jost LM, Delforge A, Bron D, Gmür J, Oelz O, Sauter C, Stryckmans P, Klastersky J (1989) Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors. Eur J Cancer Clin Oncol 25:965–972
Stoter G (1989) Treatment of disseminated renal cell cancer with interleukin-2, lymphokine-activated killer cells, and alpha-interferon. In: The Cleveland Clinic Foundation and Cancer Center (ed): The First International Symposium on Immunobiology of Renal Cell Carcinoma, 6–7.11.1989, pp 109–120
Waxman J, Thomas H (1990) Metastatic renal cell cancer – is the outlook really improving? Postgrad Med J 66:435–440
Whitehead RP, Ward D, Hemingway L, Hemstreet GP III, Bradley E, Konrad M (1990) Subcutaneous recombinant interleukin 2 in a dose-escalating regimen in patients with metastatic renal cell adenocarcinoma. Cancer Res 50:6708–6715.